Financials Nxera Pharma Co., Ltd. OTC Markets

Equities

SOLTF

JP3431300007

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 12:20:04 2024-06-20 EDT			5-day change	1st Jan Change
9.43 ^USD	-5.70%		-.--%	-5.70%

06-27	Nxera Pharma Co Achieves Key R&D Milestone in Collaboration with AbbVie; Secures $10 Million Payment	MT
06-27	Nxera Pharma Co., Ltd. Receives USD 10 Million from AbbVie as Collaboration Targeting Neurological Diseases Achieves First R&D Milestone	CI

Valuation

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Capitalization ¹	167,282	145,054	155,210	175,151	127,103	140,966	-	-
Enterprise Value (EV) ¹	153,786	121,669	124,394	138,328	152,011	158,348	126,912	120,942
P/E ratio	116 x	95.9 x	325 x	457 x	-16.3 x	60.5 x	26.6 x	18.2 x
Yield	-	-	-	-	-	-	-	0.37%
Capitalization / Revenue	17.2 x	16.4 x	8.76 x	11.3 x	9.96 x	3.85 x	3.61 x	3.12 x
EV / Revenue	15.8 x	13.8 x	7.02 x	8.88 x	11.9 x	4.33 x	3.25 x	2.68 x
EV / EBITDA	82.1 x	53.4 x	24.6 x	28.9 x	-21.6 x	32.2 x	16.4 x	11.8 x
EV / FCF	48.1 x	26.6 x	18 x	12.6 x	-2.2 x	30.7 x	15.2 x	11.7 x
FCF Yield	2.08%	3.76%	5.55%	7.95%	-45.4%	3.26%	6.57%	8.57%
Price to Book	3.71 x	2.77 x	2.7 x	3.02 x	1.9 x	2.07 x	1.92 x	1.76 x
Nbr of stocks (in thousands)	77,053	80,586	81,518	81,923	89,446	89,902	-	-
Reference price ²	2,171	1,800	1,904	2,138	1,421	1,568	1,568	1,568
Announcement Date	20-02-13	21-02-12	22-02-10	23-02-14	24-02-13	-	-	-

¹JPY in Million²JPY

Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net sales ¹	9,726	8,842	17,712	15,569	12,766	36,595	39,046	45,157
EBITDA ¹	1,873	2,278	5,053	4,781	-7,048	4,914	7,758	10,210
EBIT ¹	384	928	3,775	3,436	-9,526	3,123	4,375	8,046
Operating Margin	3.95%	10.5%	21.31%	22.07%	-74.62%	8.53%	11.2%	17.82%
Earnings before Tax (EBT) ¹	534	1,622	433	1,078	-10,680	2,999	6,023	7,921
Net income ¹	1,432	1,479	475	382	-7,913	-851.6	2,538	6,208
Net margin	14.72%	16.73%	2.68%	2.45%	-61.98%	-2.33%	6.5%	13.75%
EPS ²	18.70	18.77	5.860	4.680	-87.18	25.93	58.99	86.10
Free Cash Flow ¹	3,195	4,580	6,902	10,995	-69,064	5,154	8,336	10,370
FCF margin	32.85%	51.8%	38.97%	70.62%	-541%	14.08%	21.35%	22.97%
FCF Conversion (EBITDA)	170.58%	201.05%	136.59%	229.97%	-	104.9%	107.46%	101.57%
FCF Conversion (Net income)	223.11%	309.67%	1,453.05%	2,878.27%	-	-	328.42%	167.05%
Dividend per Share ²	-	-	-	-	-	-	-	5.875
Announcement Date	20-02-13	21-02-12	22-02-10	23-02-14	24-02-13	-	-	-

¹JPY in Million²JPY

Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December	2019 S2	2020 S1	2021 S1	2021 Q4	2021 S2	2022 Q1	2022 Q2	2022 S1	2022 Q3	2022 Q4	2022 S2	2023 Q1	2023 S1	2023 Q3	2023 Q4	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2025 Q1	2025 Q2
Net sales ¹	4,670	2,516	3,123	14,122	14,589	1,119	1,338	2,457	6,184	6,928	13,112	943	2,146	3,328	7,292	4,611	6,000	6,700	14,100	-	-
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-2,093	-	-	-	-	-
EBIT ¹	-347	-1,136	-1,849	8,043	5,624	-2,206	-	-3,804	3,189	4,051	7,240	-1,964	-4,168	-3,554	-1,534	-3,076	-4,100	-4,500	6,700	-	-
Operating Margin	-7.43%	-45.15%	-59.21%	56.95%	38.55%	-197.14%	-	-154.82%	51.57%	58.47%	55.22%	-208.27%	-194.22%	-106.79%	-21.04%	-66.71%	-68.33%	-67.16%	47.52%	-	-
Earnings before Tax (EBT) ¹	242	-1,270	-1,393	4,585	1,826	-2,497	-	-4,282	1,174	4,186	5,360	-1,863	-3,760	-4,105	-2,815	-2,796	-4,150	-4,550	6,650	-	-
Net income ¹	1,037	-2,117	-2,297	2,300	2,772	-2,070	-	-3,538	313	3,607	3,920	-1,402	-2,060	-4,925	-928	-3,281	-5,550	-6,050	8,950	-	-
Net margin	22.21%	-84.14%	-73.55%	16.29%	19%	-184.99%	-	-144%	5.06%	52.06%	29.9%	-148.67%	-95.99%	-147.99%	-12.73%	-71.16%	-92.5%	-90.3%	63.48%	-	-
EPS ²	-	-27.45	-28.38	-	-	-25.39	-	-43.33	3.870	-	-	-17.11	-25.13	-59.92	-2.130	-36.68	-67.26	-73.32	108.5	-	-
Dividend per Share ²	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Announcement Date	20-02-13	20-08-13	21-08-12	22-02-10	22-02-10	22-05-13	22-08-10	22-08-10	22-11-11	23-02-14	23-02-14	23-05-12	23-08-04	23-11-10	24-02-13	24-05-09	-	-	-	-	-

¹JPY in Million²JPY

Estimates

Balance Sheet Analysis

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net Debt ¹	-	-	-	-	24,908	17,382	-	-
Net Cash position ¹	13,496	23,385	30,816	36,823	-	-	14,054	20,024
Leverage (Debt/EBITDA)	-	-	-	-	-3.534 x	3.538 x	-	-
Free Cash Flow ¹	3,195	4,580	6,902	10,995	-69,064	5,154	8,336	10,370
ROE (net income / shareholders' equity)	3.3%	3%	0.87%	0.7%	-11.5%	5.42%	8.14%	8.36%
ROA (Net income/ Total Assets)	2.48%	2.44%	0.55%	1.1%	-8.32%	6.6%	2.85%	3.75%
Assets ¹	57,834	60,703	86,679	34,798	95,065	-12,904	89,173	165,563
Book Value Per Share ²	585.0	650.0	705.0	707.0	747.0	759.0	818.0	889.0
Cash Flow per Share ²	38.10	35.90	28.30	21.10	-57.10	73.00	137.0	160.0
Capex ¹	271	92	193	102	804	1,529	1,600	1,763
Capex / Sales	2.79%	1.04%	1.09%	0.66%	6.3%	4.18%	4.1%	3.9%
Announcement Date	20-02-13	21-02-12	22-02-10	23-02-14	24-02-13	-	-	-

¹JPY in Million²JPY

Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Nxera Pharma Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1,568 JPY

Average target price

2,111 JPY

Spread / Average Target

+34.64%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
CSL LIMITED	+2.08%	95.18B
SAMSUNG BIOLOGICS CO.,LTD.	-0.13%	37.55B
BIOGEN INC.	-10.43%	33.75B
UCB	+77.76%	28.2B
BIOMARIN PHARMACEUTICAL INC.	-14.82%	15.63B
INCYTE CORPORATION	-3.06%	13.63B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-12.76%	11.5B
ALTEOGEN INC.	+181.73%	10.81B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-53.92%	9.23B

Biopharmaceuticals